{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polycystic-ovary-syndrome/management/management-adolescents/","result":{"pageContext":{"chapter":{"id":"762c879d-8353-5b98-98e3-cd5e9dd9238e","slug":"management-adolescents","fullItemName":"Scenario: Management - adolescents","depth":2,"htmlHeader":"<!-- begin field 2bf513dc-d778-40c0-bc0b-a9670152794d --><h2>Scenario: Management of polycystic ovary syndrome in adolescents</h2><!-- end field 2bf513dc-d778-40c0-bc0b-a9670152794d -->","summary":"Covers the management of PCOS and associated disorders in adolescents. It also covers the management of adolescents who are deemed 'at risk' but not yet diagnosed with PCOS (including those with PCOS features before combined oral contraceptive (COC) pill commencement, those with persisting features and those with significant weight gain in adolescence).","htmlStringContent":"<!-- begin item 8bb95731-18bc-4314-a64e-a96701527779 --><!-- begin field faf70d0f-adb9-4b4e-9d02-acbc0157fd6e --><p>From age 12 years to 17 years (Female).</p><!-- end field faf70d0f-adb9-4b4e-9d02-acbc0157fd6e --><!-- end item 8bb95731-18bc-4314-a64e-a96701527779 -->","topic":{"id":"daaf23b6-59bf-5fa9-96d9-6d98f028d2bd","topicId":"90f70ae3-1caf-4e74-8397-cf2655cfb10c","topicName":"Polycystic ovary syndrome","slug":"polycystic-ovary-syndrome","lastRevised":"Last revised in September 2018","chapters":[{"id":"6f41b5a4-2e7e-5469-91c8-15331570cb8c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ad66803-f217-58c6-ad92-d9db6491cb26","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"132cf0f7-983a-59b8-aa99-10f350089b7c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d45a2f22-c9b6-5ee0-afb6-8ae3d0397d9f","slug":"changes","fullItemName":"Changes"},{"id":"e3852569-27c3-5e63-ab2f-2b92dcfe5262","slug":"update","fullItemName":"Update"}]},{"id":"f1fe2489-77fe-5403-977f-d3603e5bae1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"048d9ada-61af-59a9-971e-42aed733010a","slug":"goals","fullItemName":"Goals"},{"id":"845cd360-b1c4-50ee-a60f-5ec2ce05b2b8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6bed55f9-2ee7-578e-8770-b9a5e2053955","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0afb7a34-d84c-5ad9-bcc3-0dc5345cd2b8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7587b9f-e03a-5ba0-b6c5-173412097eb9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b7749edb-c354-5cb9-adc7-04cbe456d37d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"390c9f6a-9392-5672-8a5d-2945f5be467d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5ae79977-6f68-54e7-bae5-d3a83aa4bad7","slug":"definition","fullItemName":"Definition"},{"id":"86ec422e-1b3a-5c12-b4df-64886e831aea","slug":"causes","fullItemName":"Causes"},{"id":"87943c47-132e-5d7b-bba7-9f5fd8d2fdd8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fd9eddac-eb60-523a-9a51-e94719b6fef4","slug":"complications","fullItemName":"Complications"},{"id":"104e8e2a-4d4d-5fc6-b68f-5337dd3ccc87","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26e7fb06-0e4c-5c05-aea8-632061b95e52","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6f9e9e17-1a64-5142-813c-89d3dc869c6d","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"483e27e7-00c5-5c3a-b61b-d00edbcafdd7","slug":"investigations","fullItemName":"Investigations"},{"id":"6a10f0bc-d2b9-504d-beb4-a033a4cfb16b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"82ce27d1-1cdc-5a75-8d26-8bbb3d8d62d7","fullItemName":"Management","slug":"management","subChapters":[{"id":"5c7d454c-e837-5db4-96b6-d7259cedcbb1","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"762c879d-8353-5b98-98e3-cd5e9dd9238e","slug":"management-adolescents","fullItemName":"Scenario: Management - adolescents"}]},{"id":"980e12cc-a3a7-5006-9004-9a3817403978","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8c324c3d-d93a-5a1b-9a8f-070221373b1a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0096e783-16f8-5f5a-9660-d3685b777a10","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"af33ae46-9b14-5c06-98b3-689fc80c683f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"61bd6f68-6b5a-5980-aec9-07bcbf6dc232","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3d02f180-e5e5-5a10-a991-a415041c663f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17c9b913-2bf1-5468-a926-0f8643a69cc1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"696b4fff-16f7-5d8a-a5d1-da81a7a53ffc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"82ce27d1-1cdc-5a75-8d26-8bbb3d8d62d7","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"165416e1-ae9c-5da1-abde-49138907c81a","slug":"managing-pcos-in-adolescents","fullItemName":"Managing PCOS in adolescents","depth":3,"htmlHeader":"<!-- begin field 86ca8959-d070-4601-bc26-a96701527956 --><h3>How should I manage polycystic ovary syndrome in adolescents?</h3><!-- end field 86ca8959-d070-4601-bc26-a96701527956 -->","summary":null,"htmlStringContent":"<!-- begin item 217bf86a-c894-4fba-aacf-a96701527956 --><!-- begin field 43c16c97-ed58-4f44-bf71-a96701527956 --><ul><li><strong>In adolescents with a clear diagnosis of polycystic ovary syndrome (PCOS):</strong><ul><li><strong>Offer advice on the possible long-term <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">complications</a> of PCOS,</strong> including type 2 diabetes and cardiovascular disease (CVD).<ul><li>Encourage a healthy lifestyle to reduce the risk of these complications and to help improve the clinical features of PCOS.</li><li>For girls who are overweight or obese, offer advice on weight loss or consider referral to a dietitian. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li>Explain that weight loss may reduce hyperinsulinism and hyperandrogenism, reduce the risk of type 2 diabetes and CVD, and result in menstrual regularity.</li></ul></li><li><strong>Offer referral for screening for:</strong><ul><li>Impaired glucose tolerance and type 2 diabetes. </li><li>Cardiovascular risk factors. </li></ul></li><li><strong>Ask about snoring and daytime fatigue/somnolence.</strong><ul><li>If there are symptoms of obstructive sleep apnoea, refer for investigation and treatment.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a> for more information.</li></ul></li><li><strong>Ask about emotional well being, and manage as appropriate.</strong><ul><li>Screen for depression and anxiety, where appropriate. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression-in-children/\">Depression in children</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for more information.</li><li>Consider the possibility of the following:<ul><li>Psychosexual problems — hirsutism, obesity, and oligomenorrhoea may lead to feelings of being unattractive, and loss of feminine identity.</li><li>Negative body image — women with PCOS may feel less physically attractive, physically fit or healthy and may be less satisfied with their body size than women without PCOS.</li><li>Eating disorders — these include anorexia nervosa; bulimia nervosa, binge-eating disorder, and atypical eating disorders. See the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/eating-disorders/\">Eating disorders</a>.</li></ul></li></ul></li><li><strong>Manage <strong>the clinical features</strong> <strong>of PCOS.</strong></strong><ul><li>Consider prescribing the combined oral contraceptive (COC) pill alone for management of clinical hyperandrogenism and/or irregular menstrual cycles, provided there are no contraindications.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for prescribing information on COCs, including contraindications and cautions, choice, risks and adverse effects, and drug interactions.</li></ul></li></ul></li><li><strong>Provide sources of additional information and support. </strong>For example:<ul><li>Information on PCOS are available from:<ul><li>The Royal College of Obstetricians and Gynaecologists (RCOG) website (www.rcog.org.uk): <a data-hyperlink-id=\"4c54ce56-014b-4b6f-854f-a95f00cb5582\" href=\"https://www.rcog.org.uk/globalassets/documents/patients/patient-information-leaflets/gynaecology/pi-pcos.pdf\">Polycystic ovary syndrome: what it means for your long-term health</a>.</li><li>NHS A-Z (www.nhs.uk): <a data-hyperlink-id=\"4c363da2-b2bd-4693-abdc-a95f00cb55d8\" href=\"https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/\">Polycystic ovary syndrome</a>.</li></ul></li><li>Support groups for people with PCOS include:<ul><li>PCOS Challenge: The National Polycystic Ovary Syndrome Association (<a data-hyperlink-id=\"52cac0f3-2b9d-42d9-9b67-a96700c58c1f\" href=\"https://www.pcoschallenge.org/about-pcos-challenge/\">www.pcoschallenge.org</a>).</li><li>Verity (<a data-hyperlink-id=\"e7448387-1932-4df7-ab2c-a96700c58c95\" href=\"https://www.verity-pcos.org.uk/about-us.html\">www.verity-pcos.org.uk</a>).</li></ul></li></ul></li></ul><!-- end field 43c16c97-ed58-4f44-bf71-a96701527956 --><!-- end item 217bf86a-c894-4fba-aacf-a96701527956 -->","subChapters":[{"id":"c111d7e6-3422-51e2-8ee5-5d64318bd737","slug":"basis-for-recommendation-bfa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 46b07a15-5ece-4e34-9dec-a96701527957 --><h4>Basis for recommendation</h4><!-- end field 46b07a15-5ece-4e34-9dec-a96701527957 -->","summary":null,"htmlStringContent":"<!-- begin item bfa174c3-e196-41d2-9e02-a96701527957 --><!-- begin field 3e85c3bf-4c39-45e7-b9fb-a96701527957 --><p>These recommendations are based on the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International Polycystic Ovary Syndrome (PCOS) Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>] and <em>The Diagnosis of Polycystic Ovary Syndrome during Adolescence, </em>which represents the consensus of paediatric endocrine and adolescent medicine experts representing paediatric subspecialty societies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Witchel, 2015</a>]. </p><h5>Encouraging a healthy lifestyle</h5><ul><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Healthy lifestyle behaviours (including healthy eating and regular physical activity) should be recommended in all those with PCOS to achieve and/or maintain a healthy weight and to optimize hormonal outcomes, general health, and quality of life.</li><li>Lifestyle intervention (preferably multicomponent, including diet, exercise, and behavioural strategies) should be recommended in all those with PCOS and excess weight, for reductions in weight, central obesity, and insulin resistance.</li><li>Prevention of weight gain, monitoring of weight, and encouraging evidence-based and socio-culturally appropriate healthy lifestyle is important in PCOS, particularly from adolescence.</li></ul></li></ul><h5>Offering screening for impaired glucose tolerance and type 2 diabetes</h5><ul><li>The prevalence of impaired glucose tolerance and type 2 diabetes are significantly increased in PCOS, regardless of the age of the person. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>The International PCOS Network advises that glycaemic status should be assessed at baseline in all women with PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]. CKS has extrapolated this recommendation to adolescents.</li></ul><h5>Offering screening for cardiovascular risk factors</h5><ul><li>There is some evidence that cardiovascular disease (CVD) risk factors are increased in PCOS. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>CKS recommends that, in view of the possible increased risk of cardiovascular events, clinicians should give advice on measures to reduce cardiovascular risk.</li><li>The International PCOS Network advises that women with PCOS should be assessed for cardiovascular risk factors and global CVD risk. If screening reveals CVD risk factors, including obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, and lack of physical activity, the woman should be considered at increased risk of CVD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]. CKS considers that this recommendation can be extrapolated to adolescents.</li></ul><h5>Asking about snoring and daytime fatigue/somnolence</h5><ul><li>The prevalence of obstructive sleep apnoea is increased in obese adolescents with PCOS. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>The International PCOS Network advises that screening for obstructive sleep apnoea should be considered to identify and alleviate related symptoms, such as snoring, waking unrefreshed from sleep, daytime sleepiness, and the potential for fatigue to contribute to mood disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><h5>Asking about emotional well being</h5><ul><li>There is a likely increased prevalence of moderate to severe anxiety and depressive symptoms in adolescents with PCOS. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/background-information/complications/\">Complications</a> for more information.</li><li>The International PCOS Network advises that screening for anxiety and depressive symptoms should offered to all adolescents and women with PCOS at diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><h5>Managing clinical features of PCOS</h5><ul><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Provided there are no contraindications the combined oral contraceptive (COC) pill alone should be considered in adolescents with a clear diagnosis of PCOS for management of clinical hyperandrogenism and/or irregular menstrual cycles.</li><li>When deciding on a treatment, the person’s personal characteristics, preferences, and values should be considered, as well as the benefits, adverse effects, and contraindications of the treatment.</li><li>The lowest effective oestrogen doses (such as 20–30 micrograms of ethinyloestradiol or equivalent) and natural estrogen preparations should be considered whilst balancing efficacy, metabolic risk profile, adverse effects, cost, and availability.</li><li>The generally limited evidence on effects of COCs in PCOS should be considered, with practice informed by general population guidelines.</li><li>PCOS specific risk factors, such as high body mass index, hyperlipidemia, and hypertension, need to be considered.</li></ul></li></ul><h5>Providing sources of additional information and support</h5><ul><li>Providing sources of additional information and support is a clinical consensus recommendation in the <em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><!-- end field 3e85c3bf-4c39-45e7-b9fb-a96701527957 --><!-- end item bfa174c3-e196-41d2-9e02-a96701527957 -->","subChapters":[]}]},{"id":"d5416843-664c-5552-8132-863b99c62fb9","slug":"managing-adolescents-deemed-at-risk-of-pcos","fullItemName":"Managing adolescents deemed 'at risk' of PCOS","depth":3,"htmlHeader":"<!-- begin field 050c7a7a-cdcc-4bc1-8b91-a96b00709318 --><h3>How should I manage adolescents who are deemed 'at risk' but are not yet diagnosed with PCOS?</h3><!-- end field 050c7a7a-cdcc-4bc1-8b91-a96b00709318 -->","summary":null,"htmlStringContent":"<!-- begin item a148ceb0-90f3-4b0c-880c-a96b007091ca --><!-- begin field a3857a16-a1fe-44b7-b550-a96b00709319 --><ul><li><strong>In adolescents who are deemed 'at risk' but not yet diagnosed with polycystic ovary syndrome (PCOS), </strong>including those with PCOS features before combined oral contraceptive (COC) pill commencement, those with persisting features, and those with significant weight gain in adolescence:<ul><li>Consider prescribing a COC for management of clinical hyperandrogenism and irregular menstrual cycles, provided there are no contraindications. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for prescribing information.</li><li>Reassess the girl at or before full reproductive maturity (that is, 8 years post-menarche).<ul><li>This will require withdrawing the COC for 3 months or longer to determine the persistence of hyperandrogenic anovulation, and should be accompanied by contraceptive counselling.</li></ul></li></ul></li></ul><!-- end field a3857a16-a1fe-44b7-b550-a96b00709319 --><!-- end item a148ceb0-90f3-4b0c-880c-a96b007091ca -->","subChapters":[{"id":"a2284953-4e65-5a49-8006-ea354ee87069","slug":"basis-for-recommendation-fdc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 36780925-5797-4d43-b0d2-a96b00709321 --><h4>Basis for recommendation</h4><!-- end field 36780925-5797-4d43-b0d2-a96b00709321 -->","summary":null,"htmlStringContent":"<!-- begin item fdccc476-0799-47f8-835e-a96b00709321 --><!-- begin field 3c416ee2-8485-4c48-a48e-a96b00709321 --><p>These recommendations are based on the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International Polycystic Ovary Syndrome (PCOS) Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]. </p><ul><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Provided there are no contraindications the combined oral contraceptive (COC) pill could be considered in adolescents who are deemed 'at risk' but not yet diagnosed with PCOS, for management of clinical hyperandrogenism and irregular menstrual cycles.</li><li>When deciding on a treatment, the person’s personal characteristics, preferences, and values should be considered, as well as the benefits, adverse effects, and contraindications of the treatment.</li><li>The lowest effective oestrogen doses (such as 20–30 micrograms of ethinyloestradiol or equivalent) and natural estrogen preparations should be considered whilst balancing efficacy, metabolic risk profile, adverse effects, cost, and availability.</li><li>The generally limited evidence on effects of COCs in PCOS should be considered, with practice informed by general population guidelines.</li><li>PCOS specific risk factors, such as high body mass index, hyperlipidemia, and hypertension, need to be considered.</li></ul></li></ul><h5>Managing the clinical features of PCOS and managing adolescents who are deemed 'at risk' but not yet diagnosed with PCOS</h5><ul><li>Combined oral contraceptives (COCs) are the mainstay of the pharmacological treatment of PCOS as they can be used to manage both menstrual disorders and androgen excess symptoms (such as acne and hirsutism). Progestogens, usually given cyclically, also have a role in the management of menstrual dysfunction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>].</li><li>The International PCOS Network advises that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>Provided there are no contraindications:<ul><li>The COC alone should be considered in adolescents with a clear diagnosis of PCOS for management of clinical hyperandrogenism and/or irregular menstrual cycles.</li><li>The COC could be considered in adolescents who are deemed 'at risk' but not yet diagnosed with PCOS, for management of clinical hyperandrogenism and irregular menstrual cycles.</li></ul></li><li>When deciding on a treatment, the woman’s personal characteristics, preferences, and values should be considered, as well as the benefits, adverse effects, and contraindications of the treatment.</li><li>The lowest effective oestrogen doses (such as 20–30 micrograms of ethinyloestradiol or equivalent) and natural estrogen preparations should be considered whilst balancing efficacy, metabolic risk profile, adverse effects, cost, and availability.</li><li>The generally limited evidence on effects of COCs in PCOS should be considered, with practice informed by general population guidelines.</li><li>PCOS specific risk factors, such as high body mass index, hyperlipidemia, and hypertension, need to be considered.</li></ul></li><li>The information on withdrawing the COC to determine the persistence of hyperandrogenic anovulation, and contraceptive counselling are based on expert opinion in a review article on the diagnosis of PCOS in adolescents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Rosenfield, 2015</a>].</li></ul><!-- end field 3c416ee2-8485-4c48-a48e-a96b00709321 --><!-- end item fdccc476-0799-47f8-835e-a96b00709321 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}